Products Liability
Our legal team is currently examining cases involving Mounjaro lawsuits concerning patients with gallbladder disease or gastrointestinal issues such as gastroparesis or cyclic vomiting syndrome.
Mounjaro, known as semaglutide in its generic form, is a popular prescription medication used for managing type-2 diabetes and weight control. Recent research has indicated that the use of Mounjaro, especially in higher doses, may lead to the formation of gallstones and gallbladder disease, often necessitating surgical intervention for gallbladder removal. Mounjaro use has been linked to gastroparesis (stomach paralysis), and other stomach conditions.
If you took Mounjaro for weight loss and suffered gallbladder or gastrointestinal problems, contact us for a free case evaluation. Call us at 800-553-8082 or contact us online.
About Mounjaro
Mounjaro is a medication specifically developed for the treatment of Type 2 diabetes. Administered via a weekly under-the-skin injection, it belongs to a class of antidiabetic drugs that operate by stimulating the production and release of certain intestinal hormones, thereby prompting the body to release insulin.
Eli Lilly, one of the leading pharmaceutical companies globally, holds the patent for Mounjaro. Approved for medical use in the United States as recently as May 2022, Mounjaro was a groundbreaking new drug, one of the first of its kind to win FDA approval.
Although initially approved solely for diabetes treatment, Mounjaro has recently gained popularity among healthcare professionals for its potential to manage weight loss in obese patients. This “off-label” use for weight loss mirrors similar trends observed with diabetes medications like Ozempic and Wegovy.
Mounjaro Has Been Linked to Gallbladder and Gastrointestinal Problems
An expanding body of clinical research indicates that the use of Mounjaro can lead to severe gastrointestinal and gallbladder complications. The risk of encountering these issues is particularly high when Mounjaro is used for weight loss purposes, especially at higher dosages.
Mounjaro has been associated with the onset of several serious and potentially life-threatening health conditions, including:
– Gastroparesis: Referred to as “stomach paralysis,” this medical condition entails abnormal muscle movement in the stomach, resulting in slowed or halted stomach motility and improper emptying. Gastroparesis can lead to significant discomfort and potentially serious complications.
– Gastroenteritis: Characterized by infection and inflammation within the digestive system, gastroenteritis manifests with symptoms such as stomach cramps, diarrhea, and vomiting. Dehydration is a primary concern associated with this condition.
– Gallbladder Disease: Mounjaro and similar medications have been linked to the development of gallbladder disease, involving chronic inflammation of the gallbladder and the formation of gallstones. This condition can be highly painful and may necessitate surgical removal of the gallbladder.
The FDA has recently issued a major “boxed” warning regarding Mounjaro, emphasizing its potential association with gallbladder disease. This type of warning signifies the highest level of alert issued by the FDA. Anyone who started using Mounjaro after the new black box warning will likely not be able to bring a lawsuit.
Mounjaro Lawsuits
An increasing number of product liability lawsuits concerning Mounjaro are currently underway, and more are getting filed. These legal actions are being filed by individuals who took Mounjaro for weight loss and subsequently experienced some of the gastrointestinal or gallbladder complications detailed above.
The primary basis for these Mounjaro lawsuits is that the manufacturer negligently failed to provide adequate warning about the risks of gallbladder and gastrointestinal injuries. Plaintiffs assert that Eli Lilly was aware, or should have been aware, of the potential health risks, such as gastroparesis or gallbladder disease, associated with regular usage of Mounjaro at higher doses. Despite this awareness, the lawsuits contend that Eli Lilly neglected to include any warnings regarding these specific risks on Mounjaro’s drug label. Consequently, both healthcare professionals and patients were unaware of the potential dangers linked to Mounjaro use.
Mounjaro Class Action Lawsuit
In February 2024, all of the product liability lawsuits involving gallbladder and gastrointestinal injuries caused by Mounjaro (and its sister drugs Ozempic and Wegovy) were consolidated into a new “class action” MDL. The new Mounjaro MDL was assigned to Judge Gene E.K. Pratter in the Eastern District of Philadelphia.
The creation of the MDL means that all future Mounjaro lawsuits filed in federal courts around the country will be transferred into the MDL. Judge Pratter will oversee a process of consolidated or “group” discovery handled by a group of plaintiffs’ lawyers appointed to a committee. At the end of that discovery phase, a handful of sample cases will be selected for bellwether test trials. The result of these test trials are supposed to help the parties value the cases for settlement purposes.
Side Effects of Mounjaro
Mounjaro may induce various side effects, with some being more prevalent than others. While many of these side effects are transient and may persist for a few days to weeks, it’s crucial to address any prolonged, bothersome, or severe symptoms by consulting your doctor or pharmacist. The following are the most common Mounjaro side effects:
nausea
diarrhea
appetite loss
vomiting
constipation
Potential Settlement Value of Mounjaro Lawsuits
At this very premature stage of the litigation, accurately predicting the settlement value of Mounjaro lawsuits is very challenging. A significant factor contributing to this uncertainty is the question of whether the scientific evidence supporting these cases will withstand scrutiny in court, as is typical in pharmaceutical litigation.
Given these uncertainties, any estimations regarding settlement amounts or potential jury awards for Mounjaro lawsuits must be viewed as highly speculative. However, our legal team can provide an informed estimate based on certain assumptions about the case’s progression. Understanding that individuals seek insights into the potential outcomes, we aim to offer our perspective, albeit based on speculative assumptions.
With this context in mind, our attorneys suggest that a successful Mounjaro lawsuit could potentially yield a settlement value ranging from $150,000 to $300,000. This estimation is comparatively lower than our valuation for Ozempic lawsuits, primarily due to the shorter time Mounjaro has been on the market. Consequently, Mounjaro plaintiffs may have had less exposure to the drug compared to Ozempic plaintiffs, potentially weakening the strength of their cases.
Get a Mounjaro Lawyer
Mounjaro lawsuits are being filed around the country. If you have a Mounjaro lawsuit, call our attorneys today at 800-553-8082 or reach out to us online.